Lapchak v. Paradigm Biopharmaceuticals (USA), Inc.

CourtDistrict Court, S.D. California
DecidedFebruary 7, 2025
Docket3:24-cv-00143
StatusUnknown

This text of Lapchak v. Paradigm Biopharmaceuticals (USA), Inc. (Lapchak v. Paradigm Biopharmaceuticals (USA), Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lapchak v. Paradigm Biopharmaceuticals (USA), Inc., (S.D. Cal. 2025).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 PAUL A. LAPCHAK, an individual, Case No.: 24-CV-143 JLS (DDL)

12 Plaintiff, ORDER GRANTING DEFENDANTS’ 13 v. MOTION TO DISMISS

14 PARADIGM BIOPHARMACEUTICALS (ECF No. 9) (USA), INC., a Delaware corporation; and 15 DONNA SKERRETT, an individual, 16 Defendants. 17

18 Presently before the Court are Defendants Paradigm Biopharmaceuticals (USA), 19 Inc. (“Paradigm”) and Donna Skerrett’s (“Skerrett”) (collectively, “Defendants”) Motion 20 to Dismiss Plaintiff’s First Amended Complaint’s Second, Third, and Fourth Causes of 21 Action (“Mot.,” ECF No. 9) and Memorandum of Points and Authorities in Support 22 Thereof (“Mem.,” ECF No. 9-1). Plaintiff Paul A. Lapchak filed an Opposition to the 23 Motion (“Opp’n,” ECF No. 11), to which Defendants submitted a Reply (“Reply,” ECF 24 No. 13). The Court took this matter under submission without oral argument pursuant to 25 Civil Local Rule 7.1(d)(1) on June 27, 2024. ECF No. 12. Having carefully considered 26 the Parties’ arguments, Plaintiff’s First Amended Complaint (“FAC,” ECF No. 4), and the 27 law, the Court rules as follows. 28 / / / 1 BACKGROUND 2 I. Plaintiff’s Allegations 3 Plaintiff, a San Diego, California resident, is a renowned scientist, with a PhD in 4 Pharmacology. FAC ¶¶ 1, 8. Plaintiff was hired by Paradigm, a New York corporation1 5 that develops and sells drug formulas, to be its executive, holding the title of “Global Head 6 of Translational Development,” on or about October 7, 2022. Id. ¶¶ 2, 9, 11. Plaintiff 7 alleges Skerrett, a citizen of New York, and Paradigm, were each the “alter ego of the 8 other.” Id. ¶¶ 3, 7. 9 Plaintiff was an executive for approximately 12 months, and his last performance 10 evaluation indicated he “exceeded on all measures of performance.” Id. ¶ 10. On or about 11 October 3, 2023, Paradigm sent Plaintiff a new employment agreement that had not been 12 negotiated with him, and which “materially altered several aspects of the parties’ agreed- 13 upon contractual relationship.” Id. ¶ 12. On or about October 10, 2023, Plaintiff protested 14 the changes and stated he would not enter into the new agreement. Id. ¶ 13. 15 Plaintiff is also a shareholder in Paradigm and shares promised to him have not been 16 timely provided, as set forth in his Employment Agreement. Id. ¶ 14. For example, his 17 “sign on bonus” of 25,000 shares were due October 24, 2022, and were not timely provided. 18 Id. ¶ 15. His one-year anniversary 100,000 shares were due October 24, 2023, and were 19 also not timely provided. Id. ¶ 16. On October 29, 2023, Paradigm issued a “trading halt” 20 and issued a “rights offer” or “entitlement offer” to its employees, and Plaintiff timely 21 exercised his entitlement/rights offer as to the missing 125,000 shares of Paradigm stock. 22 Id. ¶ 17. Plaintiff has not received the 125,000 shares to which he is entitled, nor other 23 shares to which he is entitled under a capital raise. Id. ¶¶ 18, 19. He indicates Skerrett, “is 24 a person responsible for Paradigm’s failure to pay Lapchak wages under California law.” 25 Id. ¶ 25. 26 27 28 1 While Plaintiff alleges Paradigm is a New York corporation, the Court notes the FAC’s caption indicates 1 On November 1, 2023, at a company-wide team meeting, Plaintiff “presented an 2 overview of drug toxicity,” then on November 17, 2023, “presented a power point deck to 3 Paradigm’s safety officer, director of clinical operations, and head of osteoarthritis[,] 4 summarizing significant multi-organ toxicity of Paradigm’s drug product.” Id. ¶ 20. He 5 proceeded to inform the regulatory department of the multi-organ toxicity of the product. 6 Id. 7 Subsequently, purportedly retaliating against Plaintiff’s actions, Defendants 8 disabled Plaintiff’s access to the workplace computers. Id. ¶ 21. After Plaintiff protested, 9 Plaintiff avers Defendants “falsely claimed” Plaintiff was still an employee. Id. ¶ 21. 10 Defendants formally terminated Plaintiff on or about January 12, 2023. Id. ¶ 22. 11 II. Procedural Background 12 Plaintiff filed a Complaint on January 22, 2024. ECF No. 1. After the Parties met 13 and conferred regarding Defendants’ concerns with the Complaint, Plaintiff amended his 14 Complaint to address such concerns and filed his FAC on March 28, 2024. Mem. at 9.2 15 Defendants, dissatisfied with Plaintiff’s FAC, indicate their counsel made multiple requests 16 for Plaintiff to voluntarily agree to amend his FAC, ultimately resulting in the instant 17 Motion. Id. at 9–10. 18 Plaintiff’s FAC alleges (1) breach of contract against both Defendants; (2) breach of 19 fiduciary duties and violation of California Corporations Code Section 309 against 20 Defendant Skerrett; (3) violation of “California Whistleblower Statute” against both 21 Defendants; (4) and violations of “California Employment Law” against both Defendants. 22 See generally FAC. 23 LEGAL STANDARD 24 Rule 12(b)(6) permits a party to raise by motion the defense that the complaint 25 “fail[s] to state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). The 26

27 2 Pin citations refer to the CM/ECF page numbers electronically stamped at the top of each page of the 28 cited filing. 1 Court evaluates whether a complaint states a cognizable legal theory and sufficient facts in 2 light of Federal Rule of Civil Procedure 8(a), which requires a “short and plain statement 3 of the claim showing that the pleader is entitled to relief.” “[A] plaintiff’s obligation to 4 provide the ‘grounds’ of his ‘entitle[ment] to relief’ requires more than labels and 5 conclusions, and a formulaic recitation of the elements of a cause of action will not do.” 6 Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (alteration in original). 7 To survive a 12(b)(6) motion, then, “a complaint must contain sufficient factual 8 matter . . . to ‘state a claim to relief that is plausible on its face.’” Ashcroft v. Iqbal, 9 556 U.S. 662, 678 (2009) (quoting Twombly, 550 U.S. at 570). A claim is facially plausible 10 when the facts pled “allow[] the court to draw the reasonable inference that the defendant 11 is liable for the misconduct alleged.” Id. “[W]here the well-pleaded facts do not permit 12 the court to infer more than the mere possibility of misconduct, the complaint has alleged— 13 but it has not ‘show[n]’—‘that the pleader is entitled to relief.’” Id. at 679 (second 14 alteration in original) (quoting Fed. R. Civ. P. 8(a)(2)). 15 When reviewing a motion to dismiss under Rule 12(b)(6), the Court applies its 16 “judicial experience and common sense.” Id. (citation omitted). Further, “a district court 17 must accept as true all facts alleged in the complaint” and “draw all reasonable inferences 18 in favor of the plaintiff.” Wi-LAN Inc. v. LG Elecs., Inc., 382 F. Supp. 3d 1012, 1020 19 (S.D. Cal. 2019) (citing Retail Prop. Trust v. United Bhd. of Carpenters & Joiners of Am., 20 768 F.3d 938, 945 (9th Cir. 2014)). Where a complaint does not survive 12(b)(6) review, 21 the Court will grant leave to amend unless it determines that no modified contention 22 “consistent with the challenged pleading . . . could cure the deficiency.” DeSoto v. Yellow 23 Freight Sys., Inc., 957 F.2d 655, 658 (9th Cir.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Destfino v. Reiswig
630 F.3d 952 (Ninth Circuit, 2011)
John Desoto v. Yellow Freight Systems, Inc.
957 F.2d 655 (Ninth Circuit, 1992)
Michael Lacey v. Joseph Arpaio
693 F.3d 896 (Ninth Circuit, 2012)
Tooley v. Donaldson, Lufkin, & Jenrette, Inc.
845 A.2d 1031 (Supreme Court of Delaware, 2004)
Fisher v. San Pedro Peninsula Hospital
214 Cal. App. 3d 590 (California Court of Appeal, 1989)
Patten v. Grant Joint Union High School District
37 Cal. Rptr. 3d 113 (California Court of Appeal, 2005)
Carter v. Escondido Union High School District
56 Cal. Rptr. 3d 262 (California Court of Appeal, 2007)
Morgan v. Regents of the University of California
105 Cal. Rptr. 2d 652 (California Court of Appeal, 2000)
Kramer v. Western Pacific Industries, Inc.
546 A.2d 348 (Supreme Court of Delaware, 1988)
Love v. Motion Industries, Inc.
309 F. Supp. 2d 1128 (N.D. California, 2004)
City of Arcadia v. United States Environmental Protection Agency
265 F. Supp. 2d 1142 (N.D. California, 2003)
Blanche Paylor v. Hartford Fire Insurance Group
748 F.3d 1117 (Eleventh Circuit, 2014)
Miklosy v. Regents of the University of California
188 P.3d 629 (California Supreme Court, 2008)
Bowen v. M. Caratan, Inc.
142 F. Supp. 3d 1007 (E.D. California, 2015)
United States ex rel. Lupo v. Quality Assurance Services, Inc.
242 F. Supp. 3d 1020 (S.D. California, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Lapchak v. Paradigm Biopharmaceuticals (USA), Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/lapchak-v-paradigm-biopharmaceuticals-usa-inc-casd-2025.